natgillin/translations-raw huggingface dataset:
Form a skin fold by pinching the skin between the thumb and the forefinger.
Palcem i kažiprstom naberite kožu.
Form of lung irritation called interstitial lung disease (uncommon in European patients; common in Japanese patients: may affect up to 1 in 100 people in Europe and up to 1 in 10 in Japan).
Oblik iritacije pluća poznate pod nazivom intersticijska bolest pluća (manje često u europskih bolesnika; često u japanskih bolesnika: može se javiti kod manje od 1 na 100 osoba u Europi i kod manje od 1 na 10 osoba u Japanu).
Formal studies have not been carried out in patients with significant renal or hepatic impairment.
Istraživanja na pacijentima sa značajnim oštećenjem bubrega ili jetre nisu provedena.
Formal studies have not been conducted to evaluate the pharmacokinetics of Soliris administration in special PNH patient populations based on gender, race, age (geriatric), or renal or hepatic impairment.
Nisu provedena službena ispitivanja kako bi se procijenila farmakokinetika primjene lijeka Soliris u posebnih populacija bolesnika s PNH-om na temelju spola, rase, dobi (gerijatrijski bolesnici) ili oštećenja funkcije bubrega ili jetre.
Formal studies of the potential effect of Ilaris on human fertility have not been conducted.
Formalna ispitivanja potencijalnog učinka Ilarisa na ljudsku plodnost nisu provedena.
formaldehyde neomycin or polymyxin (antibiotics).
formaldehid neomicin ili polimiksin (antibiotici).
Formaldehyde ≤1 mg
Formaldehid ≤ 1 mg
formaldehyde. neomycin or polymyxin (antibiotics).
formaldehid neomicin ili polimiksin (antibiotici).
Format of the simplified PSUR:
Format pojednostavljenog PSUR-a:
Formation of a blood clot in a deep vein (deep vein thrombosis) or blockage of the main artery of the lung or one of its branches (pulmonary embolism), or blockage due to a blood clot elsewhere in the blood stream (embolism)
Stvaranje krvnog ugruška u dubokoj veni (duboka venska tromboza) ili blokada glavne plućne arterije ili jedne od njezinih grana (plućna embolija), ili blokada zbog krvnog ugruška negdje drugdje u krvotoku (embolija)
formation of a blood clot inside the penile vein
nastanak krvnog ugruška u veni penisa
formation of blood clots past experience of excessive gambling
razvojem krvnih ugrušaka ako ste u prošlosti imali problema s prekomjernim kockanjem
Formation of NO2
Stvaranje dušikovog dioksida (NO2)
formation of stones in the gall bladder
tvaranje kamenca u žučnom mjehuru
Formation or presence of a blood clot within a blood vessel – vein or artery (thrombosis)
Stvaranje ili prisutnost krvnog ugruška u krvnoj žili – veni ili arteriji (tromboza)
Formoterol fumarate dihydrate belongs to a group of medicines called ‘long-acting β2 adrenoceptor agonists’ or ‘bronchodilators’.
Formoterolfumarat dihidrat pripada skupini lijekova pod nazivom „dugodjelujući agonisti beta2- adrenoceptora” ili „bronhodilatatori”.
Formoterol fumarate dihydrate belongs to a group of medicines called ‘long-acting β2 adrenoceptor agonists’ or ‘bronchodilators’.
Formoterolfumarat dihidrat pripada skupini lijekova pod nazivom „dugodjelujući agonisti ß2- adrenoceptora” ili „bronhodilatator i”.
Formoterol has a high systemic clearance (approximately 1.4 L/min) and the terminal elimination half-life averages 17 hours.
Formoterol ima visok sistemski klirens (oko 1,4 l/min), a poluvrijeme eliminacije prosječno iznosi 17 sati.
Formoterol is a selective β2 adrenoceptor agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction.
Formoterol je selektivni ß2-adrenoreceptorski agonist koji kad se inhalira uzrokuje brzu i dugotrajnu relaksaciju glatkih mišića bronha u bolesnika s reverzibilnom opstrukcijom dišnih puteva.
forms a complex with the neuromuscular blocking agents rocuronium or vecuronium in plasma and thereby reduces the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction.
U plazmi stvara kompleks s neuromuskularnim blokatorom rokuronijem ili vekuronijem te tako smanjuje količinu slobodnog neuromuskularnog blokatora koji se može vezati za nikotinske receptore neuromišićne sinapse.
forms of hormonal
kontracepcije na supresiju
Formulation
Oblik lijeka
FORMULATION BUFFER SOLUTION VIAL
BOČICA OTOPINE PUFERA ZA PRIPREMU FORMULACIJE
Formulation buffer vial: Clear colourless solution.
Bočica pufera za pripremu formulacije: bistra, bezbojna otopina.
Formulation buffer vial: Human albumin solution Sodium chloride
Bočica pufera za pripremu formulacije: otopina humanog albumina natrijev klorid
Formulation buffer vial: type I glass vial with a rubber stopper (teflon-lined bromobutyl) containing 10 ml solution.
Bočica pufera za pripremu formulacije: staklena bočica tipa I s gumenim čepom (od bromobutila obloženog teflonom) koja sadrži 10 ml otopine.
FORSTEO (see
toga, MORATE ponovno
FORSTEO 20 micrograms (µg)/ 80 microlitres solution for injection, in pre-filled pen Instructions for use
FORSTEO 20 mikrograma (µg)/ 80 mikrolitara otopina za injekciju u napunjenoj brizgalici Upute za uporabu
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen
FORSTEO 20 mikrograma/80 mikrolitara otopina za injekciju u napunjenoj brizgalici
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen Teriparatide
FORSTEO 20 mikrograma/80 mikrolitara otopina za injekciju u napunjenoj brizgalici teriparatid
FORSTEO 20 micrograms/80 microliters, injection Teriparatide
FORSTEO 20 mikrograma/80 mikrolitara, injekcija teriparatid
Forsteo can be used for up to two years.
Forsteo se može koristiti do dvije godine.
FORSTEO has no or negligible influence on the ability to drive and use machines.
FORSTEO ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
FORSTEO increased BMD at the total hip (3.6 %) compared with alendronate (2.2 %) (p<0.01), as well as at the femoral neck (3.7 %) compared with alendronate (2.1 %) (p<0.05).
FORSTEO je povećao BMD cijelog kuka (3,6%) u odnosu na alendronat (2,2%) (p < 0,01) kao i BMD vrata bedrene kosti (3,7%) u usporedbi s alendronatom (2,1%) (p < 0,05).
FORSTEO is a bone formation agent to treat osteoporosis.
FORSTEO je lijek koji djeluje na stvaranje kosti te tako liječi osteoporozu.
FORSTEO is a colourless and clear solution.
FORSTEO je bezbojna i bistra otopina.
FORSTEO is contraindicated for use during pregnancy (see section 4.3).
Primjena lijeka FORSTEO kontraindicirana je tijekom trudnoće (vidjeti dio 4.3).
FORSTEO may cause an increase in the amount of calcium in your blood or urine.
FORSTEO može povećati količinu kalcija u krvi ili mokraći.
Forsteo must not be used in patients who have other bone diseases such as Paget’s disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease.
Forsteo ne smiju uzimati bolesnici koji boluju od drugih bolesti kostiju kao što su Pagetova bolest, rak kostiju ili metastaze u kostima (rak koji se proširio na kosti), u bolesnika koji su liječeni zračenjem koje obuhvaća kosti ili u bolesnika koji boluju od hiperkalcemije (visoka razina kalcija u krvi), u bolesnika s neobjašnjeno visokim razinama alkalne fosfataze (enzim) ili teške bolesti bubrega.
Forsteo parts*
Dijelovi Forsteo brizgalice
FORSTEO should be administered once daily by subcutaneous injection in the thigh or abdomen.
FORSTEO se primjenjuje jedanput dnevno supkutanom injekcijom u bedro ili abdomen.
FORSTEO should be stored in a refrigerator (2C to 8C) at all times.
FORSTEO se uvijek mora čuvati u hladnjaku (od 2C do 8C).
FORSTEO should not be used in children and adolescents (less than 18 years).
FORSTEO se ne smije primjenjivati u djece i adolescenata (mlađih od 18 godina).
Fortacin 150 mg/ml + 50 mg/ml cutaneous spray, solution Lidocaine/Prilocaine
Fortacin 150 mg/ml + 50 mg/ml sprej za kožu, otopina lidokain/prilokain
Fortacin has no or negligible influence on the ability to drive and use machines.
Fortacin nema ili ima zanemariv utjecaj na sposobnost upravljanja vozilima i rada na strojevima.
Fortacin is a combination of two medicines (lidocaine and prilocaine).
Fortacin kombinacija je dvaju lijekova (lidokaina i prilokaina).
Fortacin is indicated for the treatment of lifelong premature ejaculation in adult men.
Fortacin indiciran je za liječenje stalne preuranjene ejakulacije u odraslih muškaraca.
Fortacin is not approved for use by women.
Fortacin nije odobren za korištenje u žena.
Fortacin is not indicated for use by women.
Fortacin nije indiciran za upotrebu u žena.
Fortacin is not recommended for use whilst your partner is pregnant unless you use a male condom, as listed above, to prevent exposure of the unborn child.
Ne preporučuje se korištenje Fortacin lijeka dok je vaša partnerica trudna, osim ako ne koristite muški kondom kako je gore navedeno, kako biste smanjili izloženost nerođenog djeteta.
Fortacin is only indicated for application to the glans penis.
Fortacin indiciran je samo za primjenu na glaviću penisa.
Fortacin may also come into contact with other mucous membranes such as your, or your partner’s, mouth, nose and throat, causing them to feel slightly numb for a short while.
Fortacin također može doći u doticaj s drugim sluznicama kao što su vaše ili usne, nos ili grlo vaše partnerice, što će dovesti do osjeta blage umrtvljenosti na kraće vrijeme.
FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs
FORTEKOR PLUS 1,25 mg/2,5 mg tablete za pse FORTEKOR PLUS 5 mg/10 mg tablete za pse
Fortekor Plus is a veterinary medicine used to treat congestive heart failure in dogs.
Fortekor Plus je veterinarsko-medicinski proizvod koji se koristi za liječenje kongestivnog zatajenja srca u pasa.
Fortekor Plus is available as tablets (pimobendan 1.25 mg/benazepril hydrochloride 2.5 mg and pimobendan 5 mg/benazepril hydrochloride 10 mg) and can only be obtained with a prescription.
Fortekor Plus je dostupan kao tablete (pimobendan 1,25 mg/benazepril hidroklorid 2,5 mg i pimobendan 5 mg/benazepril hidroklorid 10 mg) te se izdaje samo na liječnički recept.
FORTEKOR PLUS tablets can be divided into halves if needed.
FORTEKOR PLUS tablete mogu se prema potrebi podijeliti u polovice.
Forty four percent of patients in the fluticasone furoate/vilanterol 92/22 group were well controlled (ACQ7 ≤0.75) at end of treatment compared to 36% of subjects in the FF 92 micrograms group (p<0.001 95% CI 1.23, 1.82).
U 44% bolesnika u skupini koja je primala flutikazonfuroat/vilanterol od 92/22 mikrograma bolest je na kraju liječenja bila dobro kontrolirana (ACQ7 ≤0,75), a isto je zabilježeno u 36% ispitanika u skupini koja je primala flutikazonfuroat od 92 mikrograma (p<0,001 95% CI 1,23; 1,82).
Forty of forty-one (40/41) patients who completed the pivotal phase 3 study were entered in a prospective study with PROCYSBI that stayed open as long as PROCYSBI could not be prescribed by their treating physician.
Četrdeset od četrdeset jednog (40/41) ispitanika koji su završili glavno ispitivanje faze 3 ušlo je u prospektivno ispitivanje s lijekom PROCYSBI koje je ostalo otvoreno sve dok im njihov liječnik nije mogao propisati PROCYSBI.
Forty percent of the participants in Studies 1 and 2 completed the Psoriasis Symptom Diary©.
Četrdeset posto ispitanika u prvom i drugom ispitivanju ispunjavalo je Dnevnik simptoma psorijaze©.
Forty seven percent of patients had an identified complement regulatory factor mutation or auto- antibody.
U 47% bolesnika utvrđena je mutacija gena koji kodiraju regulatorni čimbenika komplementa ili autoprotutijela.
Forty-eight percent of patients had one or more ongoing infections prior to receiving treatment with clofarabine.
Prije liječenja klofarabinom u 48% bolesnika bila je prisutna jedna ili više infekcija.
Forty-eight week data showed that high levels of virologic suppression, comparable to the original treatment regimen, were maintained in patients who were randomised to change to Atripla (see Table 4).
Podaci za 48 tjedana pokazali su da su kod pacijenata koji su slučajnim odabirom prešli na uzimanje Atriple (vidjeti Tablicu 4) zadržane visoke razine virološke supresije, usporedive s prvotnim režimom liječenja.
Forty-four percent of patients experienced symptoms that could be associated with neuropathy; most were mild to moderate and were reversible upon cessation of treatment with TRISENOX.
Četrdeset i četiri posto bolesnika imalo je simptome koji su se mogli povezati s neuropatijom; većina ih je bila blaga do umjerena te su postali reverzibilni nakon prekida liječenja TRISENOXOM.
Forty-nine of the 51 nucleoside-experienced patients were previously treated with lamivudine.
Četrdeset i devet od 51 pacijenata koji su primali nukleozide bilo je prethodno liječeno lamivudinom.
Forty-nine patients were enrolled and received caspofungin at 50 mg/m2 IV once daily following a 70-mg/m2 loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis.
Od 49 bolesnika koji su primili kaspofungin u dozi od 50 mg/m2 i.v. jedanput na dan (nije smjela biti veća od 70 mg na dan) nakon udarne doze od 70 mg/m2 prvog dana, 48 je bilo uključeno u
Forty-nine patients were enrolled and received caspofungin at 50 mg/m2 IV once daily following a 70-mg/m2 loading dose on Day 1 (not to exceed 70 mg daily), of whom 48 were included in the MITT analysis.
Od 49 bolesnika koji su primili kaspofungin u dozi od 50 mg/m2 i.v. jedanput na dan (nije smjela biti veća od 70 mg na dan) nakon udarne doze od 70 mg/m2 prvog dana, 48 je bilo uključeno u MITT analizu.
Forty-one percent (41%) of patients treated with ONIVYDE across the clinical program were ≥ 65 years.
Četrdeset i jedan posto (41%) bolesnika liječenih lijekom ONIVYDE u cijelom kliničkom programu bilo je u dobi ≥ 65 godina.
Forty-one point four percent (41.4 %) (95 % CI [34.5, 48.2]) of patients in the saxagliptin and dapagliflozin combination group achieved HbA1c levels of less than 7 % compared to 18.3 % (95 % CI [13.0, 23.5]) patients in the saxagliptin group and 22.2 % (95 % CI [16.1, 28.3]) patients in the dapagliflozin group.
Vrijednost HbA1c manju od 7% postiglo je 41,4% (95% CI [34,5; 48,2]) bolesnika u skupini koja je primala kombinaciju saksagliptina i dapagliflozina, u usporedbi s 18,3% (95% CI [13,0; 23,5]) bolesnika u skupini koja je primala saksagliptin i 22,2% (95% CI [16,1; 28,3]) bolesnika u skupini koja je primala dapagliflozin.
Forty-six patients received a third course of LEMTRADA treatment at 12 mg/day or 24/mg day for 3 days at Month 24.
Četrdeset i šest bolesnika primilo je treći ciklus liječenja lijekom LEMTRADA u dozi od 12 mg/dan ili 24 mg/dan tijekom tri dana u 24. mjesecu.
Forty-two (8%) experienced a serious adverse event associated with a decreased neutrophil count.
Četrdeset i dva (8%) bolesnika imala su ozbiljnu nuspojavu povezanu sa smanjenim brojem neutrofila.
Forty-two days after the booster dose, the seroprotection rate against both strains was 98.4%.
Četrdeset i dva dana od primitka doze za docjepljivanje, stopa seroprotekcije protiv oba soja bila je 98,4%.
Forty-two percent (19/45) of patients had at least 6 months of prior lamivudine experience, 20% (9/45) of patients had prior adefovir dipivoxil experience and 9 of 45 patients (20%) had lamivudine and/or adefovir dipivoxil resistance mutations at baseline.
Četrdeset i dva posto (19/45) pacijenata prethodno su primali lamivudin tijekom najmanje 6 mjeseci, a 20% (9/45) pacijenata prethodno je bilo liječeno adefovirdipivoksilom i 9 od 45 pacijenata (20%) imalo je na početku rezistenciju na lamivudin i/ili na adefovirdipivoksil zbog mutacije.
Forxiga 10 mg film-coated tablets are yellow and diamond-shaped approximately 1.1 x 0.8 cm diagonally.
Forxiga 10 mg filmom obložene tablete su žute tablete u obliku romba s dijagonalama od približno 1,1 x 0,8 cm.
Forxiga 5 mg film-coated tablets are yellow and round with diameter of 0.7 cm.
Forxiga 5 mg filmom obložene tablete su žute i okrugle tablete promjera 0,7 cm.
Forxiga is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as:
Forxiga je u indicirana odraslih u dobi od 18 i više godina sa šećernom bolešću tipa 2 za poboljšanje regulacije glikemije kao:
Forxiga is used if your diabetes cannot be controlled with other medicines for diabetes, diet and exercise.
Forxiga se primjenjuje ako se šećerna bolest ne može kontrolirati drugim lijekovima za liječenje šećerne bolesti, dijetom i tjelovježbom.
Fosamprenavir (700 mg twice
Fosamprenavir (700 mg dvaput na
Fosamprenavir (700 mg twice daily)
Fosamprenavir (700 mg dvaput na
Fosamprenavir 1,400 mg BID
Fosamprenavir 1400 mg 2x/dan
fosamprenavir 700 mg and ritonavir 100 mg twice daily
fosamprenavir 700 mg i ritonavir 100 mg dvaput na dan
Fosamprenavir 700 mg bid (saquinavir/ritonavir 1000/100 mg bid)
700 mg dvaput na dan (sakvinavir/ritonavir 1000/100 mg dvaput na dan)
Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 fold ↑ 11 fold Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of CYP3A4 inhibition.
Fosamprenavir 700 svakih 12h 100 svakih 12h Amprenavir ↑ 2,4 puta ↑ 11 puta Ritonavir povisuje serumske razine amprenavira (iz fosamprenavira) zbog inhibicije CYP3A4.
fosamprenavir and ritonavir lopinavir/ritonavir
fosamprenavir i ritonavir lopinavir/ritonavir
fosamprenavir, the dose of Vitekta
fosamprenavirom, doza lijeka
Fosamprenavir/ ritonavir (700/100 mg BID)
ritonavir (700/100 mg
Fosamprenavir/ ritonavir (FPV+RTV)
fosamprenavir/ritonavir (FPV+RTV)
Fosamprenavir/Nelfinavir/
fosamprenavir/nelfinavir/efavirenz
Fosamprenavir/ritonavir
Fosamprenavir/ritonavi
fosamprenavir/ritonavir (maraviroc dose 300 mg
(doza maraviroka 300 mg
fosamprenavir/ritonavir (maraviroc dose 300 mg
fosamprenavir/ritonavir (doza maraviroka 300 mg
Fosamprenavir/ritonavir and Nevirapine Teva can be co- administered without dose adjustments
Fosamprenavir/ritonavir i Nevirapin Teva mogu se primjenjivati istodobno bez prilagodbe doze.
fosamprenavir/ritonavir and telaprevir (see
fosamprenavir/ritonavir s telaprevirom (vidjeti
fosamprenavir/ritonavir is not
fosamprenavira/ritonavira.
fosamprenavir/ritonavir may
fosamprenavir/ritonavir
Fosamprenavir/ritonavir/Efavirenz (700 mg twice daily/100 mg twice daily/600 mg once daily)
fosamprenavir/ritonavir/efavirenz (700 mg dvaput na dan/100 mg dvaput na dan /600 mg jedanput na dan)
Fosamprenavir/ritonavir/Emtricitabine
fosamprenavir/ritonavir/emtricitabin
Fosamprenavir/ritonavir/Tenofovir disoproxil fumarate
fosamprenavir/ritonavir/tenofovirdizoproksil fumarat
Fosamprenavir/Saquinavir/Efavirenz
fosamprenavir/sakvinavir/efavirenz
Fosamprenavir Ritonavir  (induction of UGT1A1 and CYP3A enzymes)
fosamprenavir ritonavir  (indukcija enzima UGT1A1 i CYP3A)
Fosaprepitant pharmacokinetics has not been evaluated in special populations.
Farmakokinetika fosaprepitanta nije ispitana u posebnim skupinama bolesnika.
Fosaprepitant regimen
Režim s fosaprepitantom
FOSAVANCE 70 mg/2,800 IU tablets Alendronic acid /colecalciferol
FOSAVANCE 70 mg/2800 IU tablete alendronatna kiselina/kolekalciferol
FOSAVANCE 70 mg/2,800 IU tablets are available as capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.
FOSAVANCE 70 mg/2800 IU tablete su bijele do gotovo bijele tablete oblika kapsule s oznakom kosti na jednoj strani i utisnutom oznakom '710' na drugoj.
FOSAVANCE 70 mg/5,600 IU tablets Alendronic acid /colecalciferol
FOSAVANCE 70 mg/5600 IU tablete alendronatna kiselina/kolekalciferol
FOSAVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270’ on the other.
FOSAVANCE 70 mg/5600 IU tablete su bijele do gotovo bijele pravokutne tablete zaobljenih rubova s oznakom kosti na jednoj strani i utisnutom oznakom '270' na drugoj.
FOSAVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol (vitamin D3).
FOSAVANCE je kombinirana tableta koja sadrži dvije djelatne tvari, natrijev alendronat trihidrat i kolekalciferol (vitamin D3).
FOSAVANCE is available in packs containing 2, 4, 6 or 12 tablets.
FOSAVANCE je dostupan u pakiranjima koja sadrže 2, 4, 6 ili 12 tableta.
FOSAVANCE is available in packs containing2, 4 or 12 tablets.
FOSAVANCE je dostupan u pakiranjima koja sadrže 2, 4 ili 12 tableta.
FOSAVANCE may have a moderate influence on the ability to drive and use machines in patients that experience certain adverse reactions (for example blurred vision, dizziness and severe bone muscle or joint pain (see section 4.8)).
FOSAVANCE može umjereno utjecati na sposobnost upravljanja vozilima i rada sa strojevima u bolesnica u kojih se pojave određene nuspojave (npr. zamagljen vid, omaglica i jaki bolovi u kostima, mišićima ili zglobovima (vidjeti dio 4.8)).
FOSAVANCE should not be given to children and adolescents less than 18 years of age.
FOSAVANCE se ne smije davati djeci i adolescentima mlađima od 18 godina.
FOSAVANCE should not be taken at bedtime or before arising for the day.
FOSAVANCE se ne smije uzimati navečer prije spavanja niti ujutro prije ustajanja.
FOSAVANCE should not be used in children less than 18 years of age because no data are available for the alendronic acid/colecalciferol combination.
S obzirom da nema dostupnih podataka o primjeni kombinacije alendronatne kiseline/kolekalciferola, FOSAVANCE se ne smije davati djeci mlađoj od 18 godina.
FOSAVANCE should only be swallowed after getting up for the day with a full glass of water (not less than 200 ml).
FOSAVANCE se mora progutati ujutro, nakon ustajanja, s punom čašom vode (najmanje 200 ml).
Foscan must be administered intravenously via an in-dwelling cannula in a large proximal limb vein, preferably in the antecubital fossa.
Foscan se mora primijeniti intravenski putem trajne kanile postavljene u veliku venu na gornjem ekstremitetu, po mogućnosti u lakatnoj jami.
Foscan will make you sensitive to light for about 15 days after your injection.
Zbog Foscana ćete biti osjetljivi na svjetlost približno 15 dana nakon injekcije.
foscarnet (for viral infection)
foskarnet (za virusnu infekciju)
foscarnet (for viral infection).
foskarnet (za virusnu infekciju)
foscarnet, cidofovir or tenofovir disoproxil fumarate, for viral infections pentamidine, for other types of infection.
foskarnet, cidofovir ili tenofovir disoproksil fumarat za virusne infekcije pentamidin za druge vrste infekcija.
foscarnet, ganciclovir, cidofovir (for viral infections) amphotericin B, pentamidine (for fungal infections)
foskarnet, ganciklovir, cidofovir (za virusne infekcije) amfotericin B, pentamidin (za gljivične infekcije)
foscarnet, ganciclovir, cidofovir (medicines for viral infections) amphotericin B, pentamidine (medicines for fungal infections)
foskarnet, ganciklovir, cidofovir (lijekovi za virusne infekcije) amfotericin B, pentamidin (lijekovi za gljivične infekcije)
foscarnet, ganciclovir, or cidofovir (for viral infection),
foskarnet, ganciklovir ili cidofovir (za virusnu infekciju)
four 25 mg tablets twice daily or one 100 mg tablet twice daily
četiri tablete od 25 mg dva puta dnevno ili jedna tableta od 100 mg dva puta dnevno
Four 5 mg tablets once a day
četiri tablete od 5 mg jedanput na dan
Four case reports (2 published) with very suggestive causal association were issued during the reporting period regarding rhabdomyolysis in association with levetiracetam use.
Tijekom izvještajnog razdoblja izdana su četiri izvještaja (od toga dva objavljena) o slučajevima koji ukazuju na vrlo sugestivnu uzročnu povezanost rabdomiolize i uporabe levetiracetama.
Four days after your injection, your doctor will treat your cancer with laser light.
Četiri dana nakon injekcije, liječnik će Vam obasjati karcinom laserskom svjetlošću.
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg /kg/day.
Četiri studije embrio-fetalnog razvoja provedene su u kunića s dozama od 200, 600, 800, 1200 i